The sera from 34 patients with malignant melanoma at various clinical stages of the disease were examined for the presence of circulating immune complexes (CIC) by the C1q solid-phase assay. Their urine and serum samples had been previously examined for the presence of an urinary melanoma-specific protein (MSP) and the corresponding serum antibody. Low levels of CIC (only in the third stage of the disease) and no positive correlation with the presence of MSP were found. The discordance between our and other author's data stresses again the fact that the different laboratory methods for CIC evaluation reveal in a different way the various CIC populations occurring in several diseases.
Get full access to this article
View all access options for this article.
References
1.
AmlotP.L., SlaneyJ.M., WilliamsB.D.: Circulating immune complexes and symptoms of malignant melanoma patients.Lancet, 1: 449–451, 1976.
2.
BennettC., CookeK.B.: Protein insolubilisation as an aid to the detection of melanoma antigen in human urine.Protides of the biological fluids. pp. 687–691, 24 th Colloquium, Bruges 1975. PeetersH. Ed., Pergamon Press, Oxford1976.
3.
BennettC., CookeK.B.: Melanoma-specific protein: Detection and characterization of a tumour-specific protein from melanotic urine.Aust. J. Dermatol., 19: 19–22, 1978.
4.
CarpentierN.A., LangeG.T., FiereD.M., FourniéG.J., LambertP.H., MiescherP.A.: Clinical relevance of circulating immune complexes in human leukemia.J. Clin. Invest., 60: 874–884, 1977.
5.
HayF.C., NinehamL.J., RoittI.M.: Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.Clin. Exp. Immunol., 24: 396–400, 1976.
6.
HerseyP., IsbisterJ., EdwardsA., MurrayE., AdamsE., BiggsT., MiltonG.W.: Antibody-dependent, cell-mediated cytotoxicity against melanoma cells induced by plasmpheresis.Lancet, 2: 825–826, 1976.
7.
HunterW.M., GreenwoodF.C.: Preparation of 131I-labelled human growth hormone of high specific activity.Nature, 194: 495–496, 1962.
8.
JerryL.M., RowdenG., CanoP.O., PhilipsT.M., DeutschC.F., CapekA., HartmanD., LewisM.G.: Immune complexes in human melanoma: A con-sequence of deranged immune regulation.Scand. J. Immunol., 5: 845–859, 1978.
9.
RossenN.D., ReisbergM.A., HershE.M., GuttermanJ.U.: The C1q binding test for soluble immune complexes: Clinical correlation obtained in patients with cancer.J. Natl. Cancer Inst., 58: 1205–1215, 1977.
10.
SamayoaE.A., McDuffieF.C., NelsonA.M., GoV.L.W., LuthraH.S., BrumfìeldH.W.: Immunoglobulin complexes in sera of patients with malignancy.Int. J. Cancer, 19: 12–17, 1977.
11.
SjögrenH.O., HellströmI., BansalS.C., HellströmK.E.: Suggestive evidence that the « blocking antibodies » of tumor-bearing individuals may be antigen-antibody complexes.Proc. Natl. Acad. Sci. USA, 68: 1372–1375, 1971.
12.
TheT.H., Van der GiessenM., HuigesH.A., Schraffordt KoopsH., Van WingerdenI.: Immune complexes in peripheral blood polymorphonuclear leukocytes of malignant melanoma patients.Clin. Exp. Immunol., 32: 387–391, 1978.
13.
TheofilopoulosA.N., AndrewsB.S., UristM.M., MortonD.L., DixonF.J.: The nature of immune complexes in human cancer sera.J. Immunol., 119: 657–663, 1977.
14.
YonemasuK., StroudR.M.: C1q: Rapid purification method for preparation of monospecific anti-sera and for biochemical studies.J. Immunol., 106: 304–313, 1971.
